StockData
Corcept Therapeutics Inc logo

Corcept Therapeutics Inc (CORT) stock

CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30537% above fair value
$70.07+0.85 (+1.23%)

Close on Nov 17, 2026Market cap $7.57BP/E 166.8Yield –

Corcept Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Corcept Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $109.70M, down 39.9% year over year. For fiscal 2025 it was $142.00M, down 28.4% from the year before. Over ten years it grew 46.4% a year on average. The highest annual figure on record is $198.30M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$142.00M-28.4%
FY2024Dec 31, 2024$198.30M+56.5%
FY2023Dec 31, 2023$126.68M+5.3%
FY2022Dec 31, 2022$120.32M-28.3%
FY2021Dec 31, 2021$167.89M+10.5%
FY2020Dec 31, 2020$151.97M+11.6%
FY2019Dec 31, 2019$136.12M+17.7%
FY2018Dec 31, 2018$115.67M+89.8%
FY2017Dec 31, 2017$60.94M+231.3%
FY2016Dec 31, 2016$18.39M+487.6%
FY2015Dec 31, 2015$3.13M–
FY2014Dec 31, 2014-$27.38M–
FY2013Dec 31, 2013-$37.06M–
FY2012Dec 31, 2012-$36.02M–
FY2011Dec 31, 2011-$27.40M–
FY2010Dec 31, 2010-$22.29M–
FY2009Dec 31, 2009-$17.97M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$33.54M-24.3%
Q1 FY2026Mar 31, 2026-$16.77M-451.6%
Q4 FY2025Dec 31, 2025$38.45M-36.0%
Q3 FY2025Sep 30, 2025$54.48M-25.7%
Q2 FY2025Jun 30, 2025$44.30M+7.5%
Q1 FY2025Mar 31, 2025$4.77M-79.9%
Q4 FY2024Dec 31, 2024$60.06M+986.2%
Q3 FY2024Sep 30, 2024$73.29M+38.5%
Q2 FY2024Jun 30, 2024$41.19M-2.6%
Q1 FY2024Mar 31, 2024$23.76M-8.5%
Q4 FY2023Dec 31, 2023$5.53M-83.4%
Q3 FY2023Sep 30, 2023$52.91M+57.2%
Q2 FY2023Jun 30, 2023$42.29M+134.4%
Q1 FY2023Mar 31, 2023$25.96M-26.4%
Q4 FY2022Dec 31, 2022$33.39M-32.4%
Q3 FY2022Sep 30, 2022$33.65M-30.9%
Q2 FY2022Jun 30, 2022$18.04M-59.3%
Q1 FY2022Mar 31, 2022$35.25M+38.6%
Q4 FY2021Dec 31, 2021$49.43M+40.9%
Q3 FY2021Sep 30, 2021$48.70M+60.0%
Q2 FY2021Jun 30, 2021$44.34M-16.6%
Q1 FY2021Mar 31, 2021$25.42M-23.6%
Q4 FY2020Dec 31, 2020$35.07M-27.6%
Q3 FY2020Sep 30, 2020$30.44M-20.8%
Q2 FY2020Jun 30, 2020$53.19M+108.1%
Q1 FY2020Mar 31, 2020$33.27M+40.5%
Q4 FY2019Dec 31, 2019$48.45M+125.2%
Q3 FY2019Sep 30, 2019$38.43M-13.7%
Q2 FY2019Jun 30, 2019$25.56M+68.0%
Q1 FY2019Mar 31, 2019$23.68M-31.2%
Q4 FY2018Dec 31, 2018$21.52M-13.5%
Q3 FY2018Sep 30, 2018$44.51M+307.4%
Q2 FY2018Jun 30, 2018$15.21M-2.3%
Q1 FY2018Mar 31, 2018$34.43M+260.1%
Q4 FY2017Dec 31, 2017$24.88M+444.6%
Q3 FY2017Sep 30, 2017$10.93M+22.3%
Q2 FY2017Jun 30, 2017$15.57M–
Q1 FY2017Mar 31, 2017$9.56M–
Q4 FY2016Dec 31, 2016$4.57M–
Q3 FY2016Sep 30, 2016$8.94M–

More Corcept Therapeutics figures

See a number that looks wrong?